Author + information
- Received December 3, 2015
- Revision received April 5, 2016
- Accepted April 12, 2016
- Published online July 12, 2016.
- Greg C. Flaker, MDa,∗ (, )
- Paul Theriot, BSBAb,
- Lea G. Binder, MAb,
- Paul P. Dobesh, PharmDc,
- Adam Cuker, MDd and
- John U. Doherty, MDe
- aUniversity of Missouri School of Medicine, Columbia, Missouri
- bAmerican College of Cardiology, Washington, DC
- cCollege of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska
- dPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
- eSidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania
- ↵∗Reprint requests and correspondence:
Dr. Greg C. Flaker, Department of Cardiovascular Medicine, University of Missouri-Columbia, CE 351 University Hospital, CE351, One Hospital Drive, Columbia, Missouri 65212.
Interruption of oral anticoagulation (AC) for surgery or an invasive procedure is a complicated process. Practice guidelines provide only general recommendations, and care of such patients occurs across multiple specialties. The availability of direct oral anticoagulants further complicates decision making and guidance here is limited. To evaluate current practice patterns in the United States for bridging AC, a survey was developed by the American College of Cardiology Anticoagulation Work Group. The goal of the survey was to assess how general and subspecialty cardiologists, internists, gastroenterologists, and orthopedic surgeons currently manage patients who receive AC and undergo surgery or an invasive procedure. The survey was completed by 945 physicians involved in the periprocedural management of AC. The results provide a template for educational and research projects geared toward the development of clinical pathways and point-of-care tools to improve this area of health care.
The American College of Cardiology provided funds for this project. Dr. Flaker is a consultant for Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, and Daiichi-Sankyo. Dr. Dobesh is a consultant for Janssen, Daiichi-Sankyo, Pfizer, Bristol-Myers Squibb, and Boehringer-Ingelheim. Dr. Cuker is a consultant for Amgen, Biogen-Idec, Bracco, and Genzyme; and receives grant support from Spark Therapeutics and T2 Biosystems. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received December 3, 2015.
- Revision received April 5, 2016.
- Accepted April 12, 2016.
- American College of Cardiology Foundation